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Automated ﬂow cytometrytramembranous proteolysis of amyloid precursor protein (APP), Notch and other
cellular substrates and is considered a prime pharmacological target in the development of therapeutics
for Alzheimer's disease (AD). We describe here an efﬁcient, new, simple, sensitive and rapid assay to quantify
γ-secretase activity in living cells by ﬂow cytometry using two membrane-bound ﬂuorescent probes, APP-
GFP or C99-GFP, as substrates for γ-secretase. The principle of the assay is based on the fact that the soluble
intracellular domain of GFP-tagged APP (AICD-GFP) is released from the membrane into the cytosol following
γ-secretase cleavage. Using this feature, enzymatic activity of γ-secretase could be deduced from the extent
of the membrane retention of the probe observed after plasma membrane permeabilization and washout of
the cleaved fraction. By applying two well-known γ-secretase inhibitors (DAPT and L-685,458), we validated
our assay showing that the positional GFP-based probes for γ-secretase activity behave properly when
expressed in different cell lines, providing the basis for the further development of a high-throughput and
high content screening for AD targeted drug discovery. Moreover, by co-expression of different familial AD-
linked mutated forms of presenilin – the key component of the γ-secretase complex – in cells devoid of any
endogenous γ-secretase, our method allowed us to evaluate in situ the contribution of different presenilin
variants to the modulation of the enzyme.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionAlzheimer's disease (AD) is characterized by the cerebral deposi-
tion of 38–42 amino acid peptides termed β-amyloid (Aβ).These
result from the normal proteolytic processing of the amyloid
precursor protein (APP) by β- and γ-secretases [1,2]. BACE1, a trans-
membrane aspartyl protease, is the major β-secretase, which cleaves
APP within the extracellular/luminal domain, releasing a large
soluble fragment (sAPP-β) and leaving a 99-residue C-terminal
fragment (C99-CTF) in the membrane [3]. C99 can then be further
processed in situ by γ-secretase that releases the Aβ peptides and a
cytoplasmic tail dubbed APP-intracellular domain (AICD). γ-Secretase
cleaves C99 at discrete positions, generating Aβ peptides of variable
length (from 38 to 42 amino acids). Although Aβ40 is the predominant
species, Aβ42 aggregates at a much faster rate and at lower concentra-
tions, and constitutes themajor component of amyloid plaques diffusely
deposited in the parenchyma of the AD brain [4]. Alternatively, APP can
be cut, via a non-amyloidogenic pathway, by α-secretases which
produce a soluble extracellular fragment, called sAPPα, and a mem-39 049.8276049.
l rights reserved.brane associated, 83-residue C-terminal fragment called C83. This latter
is then cleaved by γ-secretase to produce AICD and p3 peptide, which is
not involved in amyloidogenesis [5].
AICD is reported to bind different molecules and to take part in
various cellular events including APP processing and trafﬁcking, apop-
tosis, neuronal growth and regulation of gene transcription [6]. Intri-
guingly, AICD initiates at a site that is distal to the canonical γ-cleavage
site, the so-called ɛ-cleavage site. The latter is located between Leu-49
and Val-50 (Aβ numbering), in a region that exhibits a strong simila-
rity with the intramembrane cleavage site of Notch, another substrate
for γ-secretase (see below) [7]. In addition, a further APP cleavage site
(ζ), generating theAβ46 intermediate precursor of secretedAβ, has been
recently identiﬁed [8]. Pharmacological data indicate that γ-cleavage
requires preceding ɛ- and ζ-cleavages, suggesting that all of these three
events are catalysed by a single enzyme [9–11]. Moreover, the
production of equimolar amounts of AICD and Aβ from the cleavage of
APP carboxyl-terminal fragment (C99) by γ-secretase has been clearly
established [12], reinforcing the idea of a single enzymatic activity.
γ-Secretase is a multimeric enzyme made of four transmem-
brane proteins: presenilin 1 (PS1) or presenilin 2 (PS2)-derived N- and
C-terminal fragments (NTF and CTF), nicastrin, APH-1 (anterior
pharynx defective phenotype 1), and PEN-2 (presenilin enhancer 2)
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components assist each other during their biogenesis and their trafﬁc
out of the endoplasmic reticulum. All four components are required to
undergo proper post-translational maturation and to achieve stability
(reviewed in [14]). PS1 and PS2 are polytopic nine-pass transmembrane
proteins which, as catalytic members of the γ-secretase complex, play
an essential role in Aβ production [15]. Genetic mutations in the APP,
PSEN1, and PSEN2 genes are responsible for early-onset familial
Alzheimer's disease (FAD) [16], all exerting their pathogenic inﬂuence
by selectively elevating the levels of highly ﬁbrillogenic Aβ42 peptides.
In addition to APP proteolysis, PSs play a crucial role in the
intramembrane γ-secretase cleavage of a variety of type I membrane
proteins including Notch1 and homologues, Notch ligands Delta and
Jagged, ErbB-4, CD44, N- and E-cadherins [15]. In addition to the
growing number of γ-secretase substrates, accumulating evidence from
protein interaction and loss of function studies suggest that, aside from
Aβ production, PSs regulate diverse physiological functions [15].
Since the high levels of AD ﬁbrillogenic Aβ42 peptides depend on
γ-secretase activity, potent enzyme inhibitors have been identiﬁed by
screening drug libraries or by designing aspartyl protease transition-
state analogues based on the APP substrate cleavage site [17].
However, most of these compounds are not speciﬁc for γ-secretase
cleavage of APP and inhibit also the processing of the other γ-
secretase substrates, such as Notch [18]. The lack of speciﬁcity of these
molecules limits their application as possible drugs in AD therapy and
prompts the scientiﬁc community to develop new methods useful for
the screening of a number of candidate compounds on a large scale,
able to evaluate speciﬁc enzyme activity on different substrates.
Here we describe the development of an efﬁcient and quantitative
high content assay for γ-secretase activity in live cells, directed towards
either APP or Notch, designed to identify endogenous regulators, aswell
as new candidate inhibitor compounds, by means of high-throughput
screening. The use of a cell-based assay for γ-secretase activity allows
the identiﬁcation of inhibitors that interact directly with the enzyme as
well as compounds that impact upstream of enzyme activation. By
validating our assay, we show that different FAD-linked PS mutants
behave, dependently on speciﬁc substrate, as “loss of function” muta-
tions for γ-secretase activity. Moreover, when co-expressed with their
wild type counterparts, they differently keep their dominant-negative
effect on normal enzymatic activity, allowing a general distinction
between PS1 and PS2 FAD-linked mutations that could inﬂuence the
overall diverse phenotypes characterizing the two forms of the disease.
2. Materials and methods
2.1. Reagents
The γ-secretase inhibitors DAPT and L-685,458 and the caspase inhibitor z-VAD
were purchased from CALBIOCHEM (Merck KGaA, Darmstadt, Germany). The polyclonal
anti-GFP antibody ab290was purchased from abCAM (Cambridge Science Park, UK) and
the polyclonal anti-actin antibody was from SIGMA (St. Louis, MO, USA).
2.2. Plasmids construction
The C99-GFP and APP-GFP constructs were created cloning the C99 fragment cDNA
or thewholeAPP cDNA (kindly donated byDr. PaulMurphy,Mayo Clinic Jacksonville) at the
N-terminal of EGFP sequence in pEGFP-N1 vector (Invitrogen), using appropriate restriction
sites. The mC99-GFP construct was obtained by site directed mutagenesis of C99-GFP
(QuikChange Site directed mutagenesis Kit, Stratagene, La Jolla, CA), using speciﬁc primers
(forward sequence GTG-GAG-GTT-GCG-GCC-GCT-GTC-ACC-CC, reverse sequence GGG-
GTG-ACA-GCG-GCC-GCA-ACC-TCC-AC) inorder to changeAsp toAlaat aminoacidicposition
86. The obtained construct was checked by sequence analysis. The NotchΔE-GFP construct
was kindly provided by Dr. Oksana Berezovska (MassGeneral Institute for Neurodegenera-
tive Disease, Harvard Medical School). The pcDNA3 constructs, as well as the pEF6/V5-His-
TOPO ones, containing the cDNA encoding for different PS2 (M239I, N141I, T122R) or PS1
(A246E, H163R, P117L, L286V) mutants were created as previously described [19].
2.3. Cell lines and transfection
HeLa and SH-SY5Y cells were grown in DMEM supplemented with 10% FCS; wt or
PS1/PS2-null (PS1−/−, PS2−/−) mouse embryonic ﬁbroblasts (MEFs) were kindlyprovided by Dr. Bart De Strooper (Center for Human Genetics, KUL, VIB, Leuven,
Belgium) and grown in DMEM/F-12 supplemented with 10% FCS. For microscopic and
cytometric experiments cells were seeded respectively on 13mm-diameter round glass
coverslips or directly into 96-well plates, and allowed to grow to 80% conﬂuence before
transfection. Transfections were carried out using Lipofectamine™ 2000 (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer's instructions. To investigate the
effect of different inhibitors, cells, 4 h after transfection, were incubated overnight with
the indicated drug and then analyzed in Western blotting or ﬂow cytometry. For stable
protein expression, clones were isolated by using cloning cylinders and selection was
carried out with 1 mg/ml of G418 (Promega, WI, USA).
2.4. Western blotting
HeLa and SH-SY5Y cell proteins were collected after 24 h from transfection as
previously described by Giacomello et al. [20]. Immunodetection of C99-GFP, mC99-GFP
and APP-GFP, as well as their metabolic products, was carried out using the polyclonal
anti-GFP ab290 antibody from abCAM (Cambridge Science Park, UK). The proteins were
visualized using the anti-rabbit IgG peroxidase conjugated (from Chemicon Interna-
tional) and the chemiluminescent reagent ECL (Amersham Biosciences, NJ, USA). To
analyze probe subcellular distribution, cells were permeabilized for 3 min by 50 μM
digitonin in an intracellular saline solution containing 50 μM EGTA (see below) and
protease inhibitors (Roche); the supernatant was then collected (soluble fraction) and
cells on the well (membrane fraction) were washed twice with PBS before being
collected following the standard procedure. After protein determination, an equal
amount of the two fractions were loaded for SDS-PAGE and Western blotting.
2.5. Confocal microscopy
Cells on coverslips were mounted on a thermostated (37 °C) chamber (Medical
System Corp.) and placed on the stage of a confocal LSM 510 Meta system (Carl Zeiss),
with a 63 oil immersion objective (NA 1.4) and illuminated at 488 nm. Cells were
observed at the microscope after 4 h from transfection and followed for the indicated
time or, in the case of cell permeabilization (made by bathing the cells with an
intracellular saline solution containing 50 μM digitonin and 50 μM EGTA; see below),
until all the cytosolic GFP ﬂuorescence disappeared and an intracellular membrane
ﬂuorescent pattern was disclosed. Fluorescence images were acquired with a time
frame indicated in each condition. Acquisition and processing of images were done
using LSM image analysis software.
2.6. Flow cytometry
Transiently transfected (after 24 h) or stable expressing cells, treated or not
overnight with the indicated drugs, were detached by trypsin. Half of each sample was
resuspended in an extracellular saline solution (130 mM NaCl, 3.6 mM KCl, 10 mM
HEPES, 2 mM NaHCO3, 0.5 mM NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, 4.5 g/l Glucose,
pH 7.4) supplemented with 4% FCS and passed through the cytometer chamber to count
total ﬂuorescent cells; the other half sample was permeabilized by the addition of an
intracellular saline solution (130 mM KCl, 10 mM NaCl, 20 mM HEPES, 1 mM MgSO4,
5 mM succinate, pH 7.2) containing 50 μM digitonin, 50 μM EGTA and 4% FCS for 3 min
and directly passed through the cytometer chamber to quantify the cells with a
membrane-bound ﬂuorescence. The ﬂuorescent signal of GFP was measured in the FL1
channel (488 nm) of a ﬂow cytometer (FACSCalibur, equipped with HTS Automated
Micro-Titer Plate Acquisition BD, NJ, USA). The presented values (retention ratio)
represent the ratio between the number of cells with membrane-bound GFP ﬂuo-
rescence after permeabilization over the number of total ﬂuorescent cells for each
condition. Data were collected in triplicate and statistical analysis was carried out by
double tail Student's T test.
2.7. Apoptosis measurement
mC99-GFP transiently transfected cells (after 24 h) were treated overnight with the
indicated drugs. Cells were then washed with PBS and incubated in an extracellular
solution containing TMRM 200 nM and Verapamil 20 μM for 30 min at 37 °C. After
incubation, cells were detached by trypsin, resuspended in the same extracellular
solution supplemented with 4% FCS and passed through the cytometer chamber.
Fluorescence was recorded in the FL3 channel at the wavelength of 530 nm and
apoptosis was calculated as the percentage of cells without TMRM ﬂuorescence respect
to the total number of cells.
3. Results
3.1. Biochemical characterization of the recombinant GFP-based probes
for γ-secretase activity
Inorder to set up anassay tomonitor theγ-secretase activity in living
cells, we tagged a known γ-secretase substrate, the APP C-terminal
fragmentC99, aswell asAPP itself,withGFPat theirC-terminal ends (see
Materials andmethods and Fig.1). The rationalewas that the differential
Fig. 1. Differential anchorage probes (DAPs) targeting γ-secretase activity. (A) APP and its β-secretase derived fragment, C99, were tagged with GFP at their C-terminal domain. The
action of γ-secretase on C99-GFP (as well as on APP-GFP after β-secretase cutting), allows the release of Aβ in the extracellular space (or within the lumen of intracellular
compartments) and AICD-GFP fragment in the cytosol. (B) Schematic representation of cell ﬂuorescence before and after plasma membrane permeabilization (PMP) in cells with
functional or inhibited γ-secretase. Only membranous ﬂuorescence is conserved upon PMP: by comparing residual membrane-bound ﬂuorescence with the total one, measured
before permeabilization, the ﬂuorescence retention ratio is determined, as an inverse index of γ-secretase activity.
1553C. Florean et al. / Biochimica et Biophysica Acta 1783 (2008) 1551–1560retention of ﬂuorescent recombinant proteins following plasma
membrane permeabilization (coined “differential anchorage probes”,
DAPs) can be used to detect proteolytic activity: upon γ-secretase
cleavage, membrane-bound C99-GFP should release Aβ into the
extracellular space (or within the lumen of intracellular compartments)
and AICD-GFP into the cytoplasm (Fig. 1A). By plasma membrane
permeabilization, causing a loss of the soluble AICD-GFP fraction, it
should thus be possible to selectively quantify the residual ﬂuorescenceFig. 2. Characterization of the new GFP probes cutting pattern in HeLa (A) and SH-SY5Y cell
DAPT (1 μM), L-685,458 (1 μM), z-VAD (50 μM) or a combination of these drugs. Protein extra
The untreated samples (NT) reveal an efﬁcient cleavage of the probe by γ-secretase in both ce
details. (C) Protein extract fromHeLa cells transfectedwith themutated C99-GFP construct (m
(D) Western blotting of APP-GFP transfected HeLa cells. A band corresponding to the full-len
shown in the untreated sample (NT). See Results for details.membrane retention that is a directmeasurementofγ-secretase activity
(Fig. 1B).
We ﬁrst determined whether the two GFP constructs were good
substrates forγ-secretase, asexpected.HeLaandSH-SY5Ycell lineswere
transiently transfected with either C99-GFP or APP-GFP cDNA and
treated or not with different enzyme inhibitors (Fig. 2).Western blots of
control, untreated C99-GFP expressing HeLa cells show different bands
(Fig. 2A, lane NT, anti-GFP antibody). By comparing this pattern withs (B). Cells were transiently transfected with the GFP probe, and treated overnight with
cts were separated by electrophoresis, blotted and analyzed with an anti-GFP antibody.
ll models, as demonstrated by the presence of the 35 kDa AICD-GFP band. See Results for
C99-GFP), lacking the consensus sequence for caspases cleavage, analyzed as in panel A.
gth protein (APP-GFP, 137 kDa) as well as the C83-GFP, AICD-GFP and free GFP bands are
Fig. 3. Differential distribution of mC99-GFP in cellular compartments upon γ-secretase
activity. HeLa cells were transfected with mC99-GFP, treated overnight, or not, with
DAPT (1 μM) and L-685,458 (1 μM) and then permeabilized with digitonin (50 μM,
3 min); the soluble and membranous fractions were collected separately. Total (Tot),
soluble (S) or membranous (M) protein fractions were analyzed by means of Western
blot with an anti-GFP antibody. Note that cell treatment with DAPT and L-685,458
changes the overall distribution of the probe, indicating that our probe works properly
(see Results for detailed description).
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γ-secretase inhibitors (lanes DAPT and L-685,458), we could identify
the different bands as follows: full-length C99-GFP (MW: 39 kDa), AICD-
GFP γ-secretase product (strongly reduced by γ-secretase inhibitors;
MW:35kDa), and twoadditional bandsatminormolecularweights. The
smallest one was equally present in all the lanes and corresponded to
free GFP (MW: 27 kDa), probably deriving from the catabolism of C99-
GFP. The remaining band corresponded to a caspase cleavage product of
C99-GFP (MW: 32 kDa), since treatment with z-VAD, a pan-caspaseFig. 4. Confocal images of HeLa cells expressing either mC99-GFP or APP-GFP. (A) Living HeL
followed up to 2 h. Fluorescence images were acquired every 360 s (from the ﬁrst image, o
cytosolic ﬂuorescence, indicating AICD-GFP release in the cytosol upon γ-secretase activit
transfection and permeabilized by digitonin. Fluorescence images were acquired every 12 s
After few minutes all the cytosolic ﬂuorescence is lost and a membranous staining is obtain
with DAPT (1 μM, overnight). (D) APP-GFP transiently transfected HeLa cells were observed
240 s (from the ﬁrst image, on the top-left of the panel, to the last one, on the bottom-righinhibitor, strongly reduced it. This is in agreementwith the presence of a
caspase cleavage site at the C-terminus of APP [21]. Interestingly, z-VAD
treatment, blocking the attack of C99-GFP by caspases, favored the
cleavage of C99-GFPbyγ-secretase evidenced bya strong increase of the
AICD-GFP band. Finally, in the DAPT and L-685,458 treated samples, a
band corresponding to C83-GFPwas observed (MW: 37 kDa), suggestive
of α-secretase activity on C99-GFP, as previously shown [22].
Fig. 2B shows similar results for SH-SY5Y cells expressing C99-GFP:
in this cell line no endogenous activity of caspases was present and the
corresponding band was missing (lane NT), while γ-secretase
inhibitors (lanes DAPTand L-685,458) induced the expected reduction
in AICD-GFP and the appearance of C83-GFP band.
To get rid of the caspase cleavage site that interferes with our assay,
we substituted the aspartic acid of the VEVD motif of C99-GFP with an
alanine (VEVA; see Materials and methods). Fig. 2C shows the Western
blot of HeLa cells expressingmutated C99-GFP (mC99-GFP): the caspase
cleavage product has disappeared and no difference between control
and z-VAD treated cells is observed (compare lanes NT and z-VAD).
Fig. 2D shows the processing of APP-GFP in HeLa cells: a higher
band (MW: 137 kDa), corresponding to the full-length APP-GFP, is
visible together with C83-GFP and AICD-GFP (bands increased and
vanished, respectively, upon cell treatment with γ-secretase inhibi-
tors; lanes DAPT and L-685,458); in addition, the caspase cleavage
product (missing in z-VAD treated cells; lane z-VAD) and free GFP are
observed. With this construct, no C99-GFP band is observed, which
may suggest a preferential cleavage of APP-GFP by α-secretase. Thisa cells transiently transfected with mC99-GFP were observed 4 h after transfection and
n the top-left of the panel, to the last one, on the bottom-right). Note the increase in
y. (B) HeLa cells transiently transfected with mC99-GFP were observed after 4 h from
(from the ﬁrst image, on the top-left of the panel, to the last one, on the bottom-right).
ed. (C) mC99-GFP stably-expressing HeLa cells treated (on the right) or not (on the left)
4 h after transfection and followed up to 1 h. Fluorescence images were acquired every
t) and an increasing cytosolic ﬂuorescence during time is disclosed. Bars, 10 μM.
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(C99), compared to the high level of α-secretase cleaved APP (C83),
was previously reported [23].
3.2. Intracellular distribution of GFP probes upon γ-secretase activity
We next analyzed the subcellular distribution (soluble/cytosolic
versus membrane-bound) of the different C99-GFP products. mC99-
GFP transfected HeLa cells were treated or not with the two γ-
secretase inhibitors (DAPT and L-685,458) and then permeabilized
with digitonin. The two resulting protein fractions (soluble and
membrane-bound) were collected separately and analyzed by means
of Western blotting, using an anti-GFP antibody (see Materials and
methods and Fig. 3). The threemain bands, i.e. C99-GFP, AICD-GFP and
free GFP, observed in nonpermeabilized control cells (lane Tot), appear
correctly sorted between soluble and membrane-bound fractions,
with the C99-GFP found only in the membrane fraction (lane M) and
the other two only in the soluble fraction (lane S). As expected, upon
DAPT or L-685,458 treatment, while AICD-GFP productionwas greatly
reduced, C83-GFP also appeared (lane Tot). This latterwas sorted in the
membrane-bound protein fraction (lane M) together with C99-GFP,
indicating that our positional probe for γ-secretase activity worked
properly. Similar results were obtained with HeLa cells expressing
APP-GFP: all the membrane-bound APP-GFP products (i.e. APP-GFP
itself and C83-GFP) were correctly distributed in the membrane
fractions whereas the expected soluble forms (AICD-GFP, the caspase
product and free GFP) were present in the supernatants collected after
cell permeabilization (data not shown).
We then tested our probes in living cells, analyzing the kinetics of
their distribution in control conditions and following DAPT treatment.Fig. 5. Cytometricmeasurement of γ-secretase activity.(A) C99-GFP ormC99-GFP transiently
(50 μM)or a combination of these drugs. Themembrane retention ratio, calculated as the num
ﬂuorescent cell number before digitonin treatment, is shown as an inverse index of γ-secret
treated as in panel A. Note that inhibition of γ-secretase by DAPT or L-685,458 is almost co
measurement of γ-secretase activity in APP-GFP transiently transfected HeLa cells. DAPT a
retention, indicating the correct behaviour of our probes. n≥3; ⁎pb0.05; ⁎⁎pb0.001.Fig. 4A shows confocal images of HeLa cells transiently expressing
mC99-GFP, analyzed 4 h after transfection and followed at the micro-
scope for up to 2 h. A diffuse cytoplasmic ﬂuorescence that increases
during time and extends to thenucleus indicates anefﬁcientγ-secretase
cleavage of mC99-GFP, due to AICD-GFP release in the cytosol. When
transfected cells were permeabilized by digitonin treatment (Fig. 4B),
washout of the soluble GFP fraction revealed an underlying pattern
corresponding to the Golgi apparatus and other cellular membranes. A
similar membrane-bound ﬂuorescence pattern was obtained in mC99-
GFP stably-expressing HeLa cells treated with DAPT: the cytosolic signal
detected in untreated cells (Fig. 4C, left panel) was strongly reduced by
DAPT and a membrane GFP pattern was revealed (Fig. 4C, right panel),
suggesting that, when γ-secretase cannot function, C99-GFP remains
membrane bound and its ﬂuorescence marks the endocellular mem-
branes where it resides. These data also suggest that in mC99-GFP
stably-expressing HeLa cells the γ-secretase activity is high since the
majority of GFP ﬂuorescence was cytosolic under resting conditions.
The intracellular processing of APP-GFP in HeLa cells is shown in
Fig. 4D: also in this case, the cytosolic ﬂuorescence increaseswith time,
suggesting an efﬁcient basal cleavage of the probe by endogenous
secretases.
3.3. Detecting γ-secretase activity by ﬂow cytometry
Once demonstrated the correct behaviour of our positional probes,
we quantiﬁed, by ﬂuorescence cytometry, their membrane retention
ratio. This value is the ratio between the fraction of cells exhibiting
membrane-bound ﬂuorescence resisting cell permeabilization, and
the fraction of ﬂuorescent cells, before digitonin treatment and re-
presents an inverse index of γ-secretase activity. Fig. 5 shows thistransfected HeLa cells were treated overnightwith DAPT (1 μM), L-685,458 (1 μM), z-VAD
ber of cellswithmembrane-boundﬂuorescence after cell permeabilization, over the total
ase activity. (B) γ-Secretase activity detected in mC99-GFP stable expressing HeLa cells
mplete in this stable cell line, as shown by a retention values over 80%. (C) Cytometric
nd L-685,458 treatments (as in panel A) induce a strong increase in probe membrane
Fig. 6. Effect ofγ-secretase and caspase inhibitors onGFP retention ratio and apoptosis. (A) HeLa cells transfectedwith GFPwere treated overnight, or not,with DAPT (1 μM), L-685,458
(1 μM) and z-VAD (50 μM) and tested for membrane ﬂuorescence retention. n≥6. (B) HeLa cells transfected with mC99-GFP were treated overnight with the indicated γ-secretase
inhibitor concentrations. Apoptotic cells were counted as the number of cells lacking TMRM ﬂuorescence over total cells in the FL3 channel (530 nm). n=3.
Fig. 7. Cytometric measurement of DAPT and L-685,458 half maximal inhibitory
concentration (IC50) for γ-secretase activity in stable expressing mC99-GFP HeLa cells.
HeLa cells were treated overnight with the indicated drug concentration and analyzed
as described in Fig. 5. For DAPT and L-685,458 an IC50 of 66 nM and 57 nM, respectively,
were determined. For each drug concentration, n=3.
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upon different treatments and subsequent cell permeabilization.
Panel A illustrates the results obtained in transiently transfected
HeLa cells with either C99-GFP (on the left) or mC99-GFP (on the
right), treated or not with DAPT, L-685,458, z-VAD or a combination of
these drugs. With both probes there is a similar, strong increase in
membrane ﬂuorescence retention when γ-secretase is inhibited by
DAPTor L-685,458; the inhibition of caspases by z-VADwas ineffective
on mC99-GFP retention, as expected, but able to weakly decrease
membrane retention of C99-GFP, probably by favoring the alternative
much faster γ-secretase turnover of the protein and thus rising AICD-
GFP production. An unspeciﬁc effect of z-VAD, such as a variation in
C99-GFP expression level or cell viability, that could explain this latter
decrease in the retention ratio is unlikely since it should be found also
in mC99-GFP transfected cells that instead do not show any difference
in retention ratio upon this treatment (right panel of Fig. 5A).
When the cells were transiently transfected with the probes the
basal ﬂuorescence retention was estimated between 30–45%
(Fig. 5A), suggesting a variability in γ-secretase activity between
single cells within the population; indeed, when HeLa cells stably-
expressing mC99-GFP were used for the same type of experiment
(Fig. 5B), basal retention was almost negligible (≤2%) and almost
complete mC99-GFP retention within cellular membranes was
achieved by inhibiting γ-secretase. This result is in agreement with
the confocal images (Fig. 4C) where, in untreated cells, all the
GFP ﬂuorescence was cytosolic, i.e. all the mC99-GFP was cut, but
upon γ-secretase inhibition the whole probe was found to be
membrane bound. Fig. 5C shows the behaviour of APP-GFP expressed
in HeLa cells: also in this case, the membrane-bound fraction,
measured upon γ-secretase inactivation, was markedly increased
and no effect was observed upon z-VAD treatment. Similar results
were obtained when the two ﬂuorescent proteins were expressed in
SH-SY5Y cells (data not shown).
In these experiments, the retention ratio of GFP alone, expressed in
both cell types,was takenasa control. Noticeably, itwasunaffectedbyall
these treatments (Fig. 6A), suggesting that the different drugs were not
able to unspeciﬁcally change the GFP ﬂuorescence distribution within
the cell.Moreover, noneof the applied treatments appeared toxic andno
cell death was induced that could have affected the readout (Fig. 6B).
Using this methodology, we estimated in live cells the half maxi-
mal inhibitory concentrations (IC50) of DAPT and L-685,458 (Fig. 7):
both γ-secretase inhibitors reached 50% of maximal ﬂuorescence
membrane retention at concentration below 0.1 μM (66 and 57 nM for
DAPT and L-685,458, respectively), values very similar to those pre-
viously determined, by different methodologies, in several cell types
[24–26].3.4. Using the GFP probes, to analyze FAD-linked PSs effect on γ-
secretase activity
To further validate our assay, we tested mC99-GFP metabolism in
mouse embryonic ﬁbroblasts (MEFs) either wild type (wt) or knock-out
for both PS1 and PS2 (MEFs KO), the key components of the γ-secretase
complex (Fig. 8). In the KO cell line no endogenous γ-secretase activity
has been reported unless rescuingof the phenotype by cell expression of
exogenous PSs [27,28]. In wt MEFs the retention ratio mC99-GFP was
similar to that seen in HeLa cells (compare Figs. 8A and 5A) whereas in
MEFs KO it was already high without any treatment and γ-secretase
inhibitors were unable to affect the membrane-bound ﬂuorescence
(Fig. 8A). The lack of a complete basal retention ratio for C99-GFP inMEF
KO is due to the fact that an endogenous catabolism of the expressed
protein, variable in entity fromcell to cell and leading to the formation of
freeGFP, is always present. Thiswas checked byWestern blotting inMEF
KO cells transiently transfected with mC99-GFP and analyzed with an
anti-GFPantibody: on the top of C99-GFP, no other cleavage product, but
free GFP, was found (data not shown), supporting the fact that in these
cells, where no γ-secretase activity is expected, no other enzyme is
actively involved in probe cleavage.
When different PSs were transiently expressed in these cells, we
could partially rescue the enzymatic activity (Fig. 8B). In particular,
bothwt formsof PSs (PS1 or PS2)were able to decrease themembrane-
bound ﬂuorescence (i.e. to release solublemC99-GFP forms), while the
Fig. 8. Effect of speciﬁc inhibitors and FAD-linked PSs expression on γ-secretase activity in MEF cells. (A) MEFs wt or knocked-out for PS1 and PS2 (MEF KO) were transiently
transfected with mC99-GFP, treated overnight with DAPT (1 μM) or L-685,458 (1 μM) and tested for ﬂuorescence retention. Note that in MEFs KO there is no effect of γ-secretase
inhibitors on probe retention ratio, which is already very high in the control condition. (B) Modulation of γ-secretase activity by PSs expression. MEFs wt or KO were transiently
transfected with mC99-GFP and the indicated PS and analyzed after 24 h. Note that in MEF KO FAD-PS mutations failed to recover γ-secretase activity, acting as loss of function
mutations. (C, D) MEF KO cells were transiently transfected with mC99-GFP together with one of the above reported PS forms and the cytometric assay was carried out after 24 h.
n≥5; ⁎pb0.05; ⁎⁎pb0.001.
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T122R) behaved as loss of function mutations. The level of expression,
as well as of endoproteolysis, of the different PSs was checked by
Western blotting and no difference was revealed in these two
parameters that could justify the lack of effect on γ-secretase activity
of the mutated forms (data not shown). Moreover, when FAD-PSs
were co-expressed with their wt counterparts at 1:1 ratio in MEFs KO
(i.e. to mimic the pathological heterozygosis), the PS1-A246E
mutant still exhibited the characteristic of a loss of function mutation,
with an effect similar to that observed when expressed alone (Fig. 8B).
Thus PS1-A246E exhibits a “dominant-negative” effect. In contrast,
PS2-T122R, when co-expressed with PS2 wt, did not modify the re-
tention ratio, suggesting its recessivity with respect to wt PS2. In wt
MEF cells, the expression of either wt or FAD-PSs had no effect on
mC99-GFP retention ratio (Fig. 8B), indicating that the presence of
endogenous γ-secretase activity may likely obscure the speciﬁc effect
of exogenous PSs.
To demonstrate that the difference between PS1-A246E and PS2-
T122R FAD mutants in modulating the γ-secretase activity, when co-
expressed with PS wt forms, is not related to the speciﬁc mutations
but could be likely due to a general feature, other PS1- and PS2-FAD
mutations were screened: PS1-H163R, PS1-L286V, PS1-P117L andPS2-M239I, PS2-N141I. Strikingly, all the PS2 proteins behaved as loss
of function mutants only when expressed alone; in fact co-expression
of PS2 wt rescued the γ-secretase activity (Fig. 8D). In contrast, PS1-
FAD forms maintained their lack of enzymatic activity even in the
presence of PS1 wt, indicating their “dominance” with respect to the
wt protein functionality (Fig. 8C). Thus, in heterozygosis, only PS1- but
not PS2-FAD mutations were able to negatively affect γ-secretase
activity.
Altogether the data here reported indicate these retention probes,
used in combination with ﬂow cytometry, as a useful and simple test
for assaying γ-secretase activity in living cells. Modulation of the
enzymatic activity by different compounds can be easily monitored
and quantiﬁed by these probes, suggesting the feasibility of their use
in a high-throughput screening approach aimed at deﬁning new
molecules as potential drugs for AD treatment. With this perspective,
it is mandatory to develop a parallel assay where Notch, the other
principal substrate for γ-secretase activity, is also monitored. Pur-
posely, ﬂow cytometric assay was carried out with HeLa, SH-SY5Y and
MEF KO cells transiently transfected with the cDNA coding for the
truncated form of Notch, lacking the ectodomain and fused to GFP
(NotchΔE-GFP; see Materials and methods and [29]) (Fig. 9). It can be
noticed that in cells with endogenous γ-secretase activity, i.e. HeLa
Fig. 9. Cytometric measurement of γ-secretase activity on NotchΔE-GFP: effect of
inhibitors and PS expression in HeLa, SH-SY5Y and MEF KO cells. Cells, transiently
transfected with the NotchΔE-GFP construct, were treated as described in Fig. 8. n≥3;
⁎pb0.05; ⁎⁎pb0.001.
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inhibition of the enzymatic activity by DAPT or L-685,458 led to a
retention ratio of only 45% on average, suggesting possible alternative
mechanisms for Notch processing. Indeed, a PS-independent Notch
signaling previously reported in PS1/2 double null cells [30] has been
here conﬁrmed in MEF KO. In this cell type, lacking γ-secretase
activity, the basal retention ratio was about 50%, indicating that half of
NotchΔE-GFP was released from cell membranes by a different, PS-
independent mechanism. In addition, when wt PS1 was expressed in
these cells, an additional Notch processing was achieved. Also in the
case of Notch probe, the expression of the FAD-linked PS1-A246E form
determined a loss of enzymatic activity. As far as PS2 protein is
concerned, two main results can be underlined. First, at variance with
wt PS1 that, once expressed inMEF KO cells, recovered the γ-secretase
activity by the same extent (∼35%) on both mC99-GFP and NotchΔE-
GFP (compare Figs. 8B and 9), wt PS2, upon expression, was less
effective on NotchΔE-GFPwith respect tomC99-GFP substrate (20 and
50% recovery of enzymatic activity compared to control, respectively;
compare Figs. 8B and 9). Secondly, PS2-T122R did not behave as a loss
of functionmutation, since it acts as thewt proteinwhen incorporated
in the γ-secretase complex (Fig. 9). Thus, γ-secretase activity seems to
depend on the speciﬁc molecular arrangement of the complex and
shows a substrate-dependent speciﬁcity.
4. Discussion
In this study, we constructed genetically encoded GFP-based
sensors that were successfully used to monitor γ-secretase activity
in living cells. Our strategy consisted in the generation of retention
probes capable to convert positional signals into intensity responses.
The method is based on the differential retention of ﬂuorescent
recombinant proteins following plasma membrane permeabilization
and is suitable for detecting a variety of molecular events, such as
proteolytic activities and changes in intracellular compartmentaliza-
tion [31]. We presented here speciﬁc retention probes targeting key
molecular steps in a cellular pathway relevant to drug development:
the γ-secretase activity.
The three membrane-bound probes used in this study (APP-GFP,
C99-GFP and NotchΔE-GFP) behaved as predicted when expressed in
living cells: upon γ-secretase activity they all release the soluble GFP-
linked product (AICD- and NICD-GFP, respectively) in the cytoplasm
allowing, upon cell permeabilization, the quantiﬁcation of the
residual membrane ﬂuorescence retention that is an inverse index
of γ-secretase activity. Noteworthy quantiﬁcation of AICD, as a value
of Aβ production by γ-secretase activity, is correct since the for-
mation of equimolar amounts of AICD and Aβ from the cleavage of
APP carboxyl-terminal fragment (C99) by γ-secretase has been
clearly established [12].The use of this assay to measure cellular γ-secretase activity has
many advantages over traditional, widely used immuno-assays, such
as ELISA and immunoprecipitation. Firstly, it is based on the mea-
surement of a stable γ-secretase product, contrary to the Aβ-antibody
assay that can be affected by factors modulating Aβ turnover and
clearance. AICD-GFP is, in fact, very stable and easily detectable by
Western blot analysis, suggesting that its catabolismby IDE [32] and/or
other proteases is greatly reduced compared to unmodiﬁed AICD, as
demonstrated also for other AICD-fused proteins [23]. Secondly, the
genetically encoded probes aremore easily obtained and cheaper than
the commercial kits available for quantifying Aβ. Thirdly, the assay is
particularly suited for screening of novel γ-secretase modulating
drugs. The assay can be performed in a convenient 96-well microplate
format using stable probe-expressing cells and can be developed for
high-throughput systems. In addition, this approach allows a detailed
functional characterization of drug activity directly in cells, bypassing
the need for image acquisition and analysis. Thus, our retention probes
constitute a robust alternative tool for high content target identiﬁca-
tion and drug discovery that could also be applied to the study of other
membrane protein substrates for diverse cellular proteolytic activities
[31].
Similar γ-secretase assays, alternative to the most used Aβ-
antibody assays, have been previously described: all of them, however,
are cell-based reporter gene assays where the γ-secretase product
AICD, C-terminally tagged with Gal4/VP16, allows a Gal4-regulated
reporter gene (luciferase or GFP) expression [23,33–35]. Their func-
tion depends on the responsiveness of the reporter gene and shows
some disadvantages, such as background expression of the reporter
gene independent of γ-secretase activity and possible interference, by
different treatments, with the gene expression machinery as well as
with the reporter gene product itself, as in the case of luciferase [36].
Our results show that the two recombinant probes for γ-secretase
activity, mC99-GFP and APP-GFP, behave correctly when expressed in
different cell types having or not endogenous γ-secretase activity
(Figs. 2, 3, 4). In addition, the cytometric assay clearlymeasures a dose-
dependent decrease in γ-secretase cleavage upon cell treatment with
speciﬁc enzyme inhibitors, such as DAPT and L-685,458 (Figs. 5, 7, 8),
allowing an IC50 determination for both inhibitors consistent with
those obtained in previous reports [24–26]. Altogether these data
demonstrate the speciﬁc, quantitative and sensitive functioning of our
new assay for cellular γ-secretase activity readout.
To test whether the assay could identify differences in γ-secretase
activity due to changes in components of the γ-secretase complex,
we over-expressed wt and FAD-linked PS forms in MEF cells (Figs. 8,
9). In MEF wt cells we did not achieve any modulation of γ-secretase
activity by this tool, probably due to the presence of the endogenous
proteins that masks the effect of the exogenous PS forms. However, in
MEF KO cells, lacking both PS1 and PS2 and thus devoid of their own
γ-secretase, exogenous expression of wt PSs recovers the enzymatic
function. Moreover, comparing the results from the cytometric assay
carried out on both mC99-GFP and NotchΔE-GFP expressing MEF
KO cells, a certain preference of PS2-containing γ-secretase com-
plex for C99-GFP substratewas evident. Thus, it seems that, while the
γ-secretase complex having PS1, as the catalytic core, cuts equally
well NotchΔE-GFP and C99-GFP, PS2 expression drives a more
extensive recovery of the enzymatic activity on C99-GFP compared
to NotchΔE-GFP, suggesting that the PS2-containing γ-secretase
complex cuts preferentially, or to a greater extent, the amyloidogenic
substrate. Previous studies show that both PS1 and PS2, when
expressed separately, canmediate the γ-secretase production of both
AICD- and NICD-ﬂag [37]: the relative quantiﬁcation of the two
cleavages was however difﬁcult because two different antibodies
were used for the detection of the speciﬁc products. Furthermore,
using both an “in vitro” and a cellular assay on the C99 substrate, a
different behaviour of PS1-containing γ-secretase complexes, com-
pared to PS2-containing ones, in term of substrate speciﬁcity and
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two putative aspartyl class proteases may contribute to different
biological processes[38]. Indeed, the diverse phenotypes exhibited
by the PS1- and PS2-deﬁcient mice may reﬂect these differences
[39,40]. Recently, differences in speciﬁcγ-secretase inhibitor potency
determinants between PS1 and PS2 sequences were reported [41],
pointing out to the need of isoform speciﬁc therapeutic strategies for
AD treatment. The dissimilar substrate/ligand preferences of the PS1
versus PS2 γ-secretase complex could be an important issue re-
quiring further investigations: understanding the speciﬁcity of PS1
and PS2 toward different substrates and inhibitors will help to
develop selective γ-secretase inhibitors for AD therapy. On this line,
the parallel application of our cellular assay on either APP or Notch
substrates, using different cell line stably-expressing PS1- or PS2-
containing γ-secretase, could be very useful in a high-throughput
screening approach aimed at deﬁning new molecules with selective
potency toward Aβ production and Notch signaling.
Finally, our results with FAD-linked PS expression in MEF KO cells
indicate that various mutants modulate the γ-secretase activity
dependently on their co-expression with the wt counterparts: in
general all the FAD-PS here analyzed behave by themselves as loss of
γ-secretase function mutants, as recently suggested by several
authors [42–44], but only FAD-PS1 forms keep this feature when co-
expressed with the wt counterpart. The different dominance on
normal enzymatic activity could contribute to, or inﬂuence, the overall
diverse pathogenesis characterizing the FAD PS1- or PS2-linked forms
of the disease, being responsible for the more aggressive and severe
phenotype of the formers.
Altogether these data suggest our positional probes as new tools
for assaying the γ-secretase activity and deﬁning the speciﬁc con-
tribution of different isoforms, that could be part of the complex (PS1
versus PS2 or wt PSs versus FAD-linked PSs), to the enzymatic activity.
In addition, modulation of the enzyme activity by different com-
pounds could eventually be monitored and quantiﬁed, suggesting its
possible use in a high-throughput screening approach aimed at de-
ﬁning new therapeutic strategies for AD treatment.
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